Rapid induction of remission in large vessel vasculitis by IL-6 blockade: A case series

Swiss Medical Weekly

Volumn 141, Issue JANUARY, 2011, Pages

  Seitz, Michael ^a   Reichenbach, Stephan ^a,b   Bonel, Harald M ^a   Adler, Sabine ^a   Wermelinger, Felix ^a   Villiger, Peter M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Large vessel vasculitis; Remission induction; Tocilizumab

Indexed keywords

ACUTE PHASE PROTEIN; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; PREDNISONE; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; AORTA ARCH SYNDROME; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; MALE; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; DRUG ANTAGONISM; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SECRETION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; GIANT CELL ARTERITIS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; REMISSION INDUCTION;

EID: 79955751346     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13156     Document Type: Article

References (15)

1. Gonzàles-Gay MA, Garcia-Porruea C. Epidemiology of the vasculitides. Rheum Dis Clin North Am. 2001;27:729-49.
2. Gonzàles-Gay MA, Garcia-Porrua C, Llorca J, Hajeer AH, Branas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine. (Baltimore) 2000;79:283-92.
3. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49:703-8. (Pubitemid 37296477)
4. Jover JA, Hernandez-Garcia C, Morado IC, Banares A, Fernandez- Gutiérrez B. Combined treatment of giant cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106-14. (Pubitemid 32096337)
5. Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, La Valley MP. Merkel PA. Adjunctive Methotrexate for treatment of giant cell arteritis. An individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789-97.
6. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatic: a double-blind study. Ann Rheum Dis. 1986;45:136-8. (Pubitemid 16162481)
7. Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, López-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67:625-30. (Pubitemid 351571925)
8. Hoffmann GS, Cid MC, Rendt-Zagar K, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Int Med. 2007;146:621-30. (Pubitemid 351650517)
9. Emilie D, Liozon E, Crevon MC, Lavignac C, Portier A, Liozon F, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39:17-24. (Pubitemid 24152731)
10. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286-94. (Pubitemid 23303119)
11. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology. 2006;45:545-8.
12. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008;58:1197-200. (Pubitemid 351564023)
13. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 Criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122-8.
14. Arend WP, Michael BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 Criteria for the Classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129-34.
15. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, for the OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008;371:987-97.